AI assistant
ViroGates A/S — Director's Dealing 2021
Sep 3, 2021
8620_rns_2021-09-03_4245c49f-c1dc-494b-85de-1006ea027d95.pdf
Director's Dealing
Open in viewerOpens in your device viewer
ViroGates
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
3.9.2021 14:27:00 CEST | ViroGates | Managers' transactions
COMPANY ANNOUNCEMENT - No. 18-2021 - 3 September 2021
Inside Information
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, this morning received notice of the following transactions by persons discharging managerial responsibilities according to MAR art. 19. The transaction notification form is listed below.
Thomas Krarup comments on the sale of shares: "I have high confidence in the prospects for ViroGates. I remain a shareholder of ViroGates and only sold part of the shares I hold to finance subscription of shares based on my warrant program. I do not intend to sell additional shares in 2021."
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Thomas Krarup | ||
| 2. | Reason for the notification | |||
| a) | Position/status | VP Sales & Marketing | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | ViroGates A/S | ||
| b) | LEI | 5493007TX8XS56RMZD94 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | |||
| Identification code | Sales of shares | |||
| ISIN Code: DK0061030574 | ||||
| b) | Nature of the transaction | Sales | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| 194 | 500 | |||
| 205 | 2244 | |||
| 206 | 930 | |||
| 206 | 763 | |||
| 209 | 563 | |||
| d) | Aggregated information | |||
| - Aggregated volume | ||||
| - Price | 5000 shares | |||
| DKK 1,020,903 | ||||
| e) | Date of the transaction | Aug 20-30, 2021 | ||
| f) | Place of the transaction | First North Growth market Denmark (DSME) |
This announcement is also available on the company's website.
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: [email protected]
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönne
Tel. (+46) 40 200 250, email: [email protected]
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff. The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets. ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
Disclosure regulation
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, [email protected]
Attachments
- 20210903-ViroGates Comp. Ann. 18.pdf